Patricia Graham

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

Michael Wang, Jacqueline C. Barrientos, Richard R. Furman et al. · NEJM Evidence · 2021 · 77 citations

Medicine, Oncology, Pharmacology +15

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

Paul J. Hesketh, Rogério Lilenbaum, Kari Chansky et al. · Journal of Thoracic Oncology · 2007 · 51 citations · Full text

Medicine, Oncology, Chemotherapy +6

A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer

Rogério Lilenbaum, Mark A. Rubin, Joyce P. Samuel et al. · Journal of Thoracic Oncology · 2007 · 41 citations · Full text

Medicine, Oncology, Pharmacotherapy +7

A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC)

Rogério Lilenbaum, Mark A. Rubin, Joyce P. Samuel et al. · Journal of Clinical Oncology · 2004 · 25 citations

Pharmacy, Oncology, Pharmacotherapy +14

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Michael Wang, Jacqueline C. Barrientos, Richard R. Furman et al. · Blood · 2020 · 16 citations

Medicine, Oncology, Pharmacology +12